

HALE AND DORR LLP DRAFT OF MARCH 19, 2004		DOCKET NUMBER 47508.642US2 HYZ-642	APPLICATION NUMBER 09/103,745
SUBT. FOR, PTO-1449		APPLICANT AGRAWAL, Sudhir	
INFORMATION DISCLOSURE IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		FILING DATE June 24, 1998	GROUP ART UNIT 1635
SHEET	1	OF	2

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JDS	4,806,463	2/1989	Goodchild, et al.	514	44	
	5,149,797	9/1992	Pederson, et al.	536	24.5	
	5,194,428	3/1993	Agrawal, et al.	514	44	


Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JDS	93/13749	7/1993	WIPO			
	94/02498	2/1994	WIPO			
	94/26877	11/1994	WIPO			
	95/09236	4/1995	WIPO			
	96/02555	2/1996	WIPO			
	96/19572	6/1996	WIPO			

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
JDS	A1	Agrawal (1992) Trends in Biotechnology 10:152-158.
	A2	Agrawal et al (1995) Current Opinion in Biotechnology 6:12-19.
	A3	Agrawal et al. (1995) Clinical Pharmacokinetics 28:7-16.
	A4	Agrawal et al. (1987) Tetrahedron Letters 28:3539-3542.
	A5	Agrawal (1996) Trends in Biotechnology 14:376-387.
	A5	Ballas et al. (1996) Journal of Immunology 157:1840-1845.
	A7	Beaucage, In Protocols for Oligonucleotides and Analogs: Synthesis and Properties, Agrawal (editor), Humana Press, Totowa, NJ, pp.33-61.

EXAMINER JDS Schuyf	DATE CONSIDERED 6-24-03
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

SUBT. FOR, PTO-1449		HALE AND DORR LLP DRAFT OF MARCH 19, 2004		DOCKET NUMBER 47508.642US2 HYZ-642		APPLICATION NUMBER 09/103,745	
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  (USE SEVERAL SHEETS IF NECESSARY)				APPLICANT <b>AGRAWAL, Sudhir</b>			
				FILING DATE <b>June 24, 1998</b>		GROUP ART UNIT <b>1635</b>	
SHEET	<b>2</b>	OF	<b>2</b>				

JDS	A8	Boggs, R. et al, "Characterization and modulation of immuni stimulation by modified oligonucleotides," Antisense & Nucleic Acid Drug Development, Vol. 7, (October 1997), pgs. 461-471.
	A9	Dougherty et al. (1992) J. Am. Chem. Soc. 114:6254.
	A10	Habus et al. (1996) Bioorganic and Medicinal Chemistry Letters 6:1393-1398.
	A11	Iyer et al. (1996) Tetrahedron Letters 37:1539-1542.
	A12	Iyer et al. (1995) Nucleosides & Nucleotides 14:1031-1035.
	A13	Iyer et al. (1995) Tetrahedron Asymmetry 6:1051-1054.
	A14	Kandimalla et al., Nucleic Acids Research, 1997, Vol. 25, No., pp. 370-378.
	A15	Krieg et al. (1995) Nature 374:546-549.
	A16	Krieg et al. Antisense & Nucleic Acid Drug Devel. 6:133-139 (1996).
	A17	Padmapriya et al. (1994) Antisense Research & Development 4:185-189.
	A18	Paterson et al. (1977) Proc. Natl. Acad. Sci. USA 74:4370-4374.
	A19	Sproat (1995) Journal of Biotechnology 41:221-238.
	A20	Stein et al. (1996) Trends in Biotechnology 14:147-149.
	A21	Tao et al. (1995) Antisense Research & Development 5:123-129.
	A22	Torrence et al. (1993) PNAS 90:1300-1304.
	A23	Zamecnik et al. (1978) Proc. Natl. Acad. Sci. USA 75:280-284.
	A24	Zhang et al. (1995) Clinical Pharmacology and Therapeutics 58:44-53.
	A25	Zhao et al., Biochem. Pharm. 51: 173-182 (1996).
✓	A26	Zhao et al., Antisense & Nucleic Acid Drug Development 7:495-502 (1997).

EXAMINER 	DATE CONSIDERED <b>6-24-04</b>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	